Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Annaida Technologies Sa |
| Country | Switzerland |
| Start Date | Feb 01, 2021 |
| End Date | Mar 31, 2023 |
| Duration | 788 days |
| Number of Grantees | 2 |
| Roles | Third Party; Coordinator |
| Data Source | European Commission |
| Grant ID | 959600 |
EmbryoSpin is a proprietary sensor for μNMR, capable to increase the sensitivity by an order of magnitude (10x) with respect to the state-of-the-art, thus allowing the analysis of cells and materials from a completely new viewpoint.
Among the host of applications for this technology, the introduction of EmbryoSpin as a fast and effective embryo selection tool during In Vitro Fertilization (IVF) treatments has proven to represent a huge business opportunity.
In fact, in more than 1.69 million IVF procedures performed globally each year, embryologists adopt visual inspection to select the embryo that has most chances to be successfully implanted to the uterus, often leading to long time to pregnancy due the selection of the wrong embryo and repeated fertilization cycles.
With Embryospin, embryo’s metabolic activity is measured through μNMR and is used as a reliable quantitative marker of embryo’s vitality, thus increasing the chance of pregnancy after a single treatment cycle.
This is valuable for women that undergoes less fertilization cycles, and to the clinics that can enhance the number of IVF performed each year.
EmbryoSpin equipment and disposable μNMR sensors will serve up to 3,500 IVF treatments, generating 33 M€ of revenues by 2025.
Hemex Ag; Annaida Technologies Sa
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant